Herbals used for diabetes, obesity, and metabolic syndrome

Primary Care - Clinics in Office Practice

Volumn 37, Issue 2, 2010, Pages 237-254

  Najm, Wadie ^a   Lie, Désirée ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complementary and alternative medicine; Diabetes; Herbals; Metabolic syndrome; Obesity

Indexed keywords

ALKALOID; ALPHA TOCOPHEROL; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ASCORBIC ACID; CAFFEINE; CENTRAL STIMULANT AGENT; CETILISTAT; CHITOSAN; CHROMIUM; CINNAMON EXTRACT; CONJUGATED LINOLEIC ACID; EPHEDRA EXTRACT; FENPROPOREX; FLUOXETINE; FUROSEMIDE; GREEN TEA EXTRACT; GYMNEMA SYLVESTRE EXTRACT; HERBACEOUS AGENT; MAGNESIUM; MOMORDICA CHARANTIA EXTRACT; OPUNTIA EXTRACT; OPUNTIA FULGINOSA EXTRACT; PLACEBO; PRASTERONE; SOYBEAN PROTEIN; THIOCTIC ACID; TRIGONELLA FOENUM GRAECUM EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ABDOMINAL DISCOMFORT; ACUPUNCTURE; ALBUMINURIA; ALTERNATIVE MEDICINE; BARIATRIC SURGERY; BLOATING; CHINESE MEDICINE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DIETARY INTAKE; DIURESIS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EXERCISE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPNOSIS; HYPOGLYCEMIA; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; LOOSE FECES; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUT; OBESITY; OPUNTIA; OPUNTIA FULGINOSA; PAIN; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; STOMACH PAIN; STROKE; TACHYCARDIA; TASTE DISORDER;

COMPLEMENTARY THERAPIES; DIABETES MELLITUS; DIETARY SUPPLEMENTS; HUMANS; METABOLIC SYNDROME X; OBESITY; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 77952906722     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.02.008     Document Type: Review

References (116)

1. International Diabetes Federation IDF diabetes atlas 2008, International Diabetes Federation, Belgium. 3rd edition.
2. Misra A., Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008, 93(11 Suppl 1):S9-30.
3. Morrison J.A. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007, 120:340.
4. Body mass index (BMI) and cause-specific mortality. Lancet 2009, 373:1083-1096. Prospective Studies Collaboration.
5. Willet W.C. Dietary fat plays a major role in obesity: no. Obes Rev 2002, 3(2):59-68.
6. Bray G.A., Popkin B.M. Dietary fat intake does affect obesity. Am J Clin Nutr 1998, 68(6):1157-1173.
7. Howard B.V., Manson J.E., Stefanick M.L., et al. Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA 2006, 295(1):39-49.
8. Nordmann A.J., Nordmann A., Briel M., et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166(3):285-293.
9. Zazpe I., Sanchez-Tainta A., Estruch R., et al. A large randomized individual and group intervention conducted by registered dietitians increased adherence to Mediterranean-type diets: the PREDIMED study. J Am Diet Assoc 2008, 108(7):1134-1144.
10. Shai I., Schwarzfuchs D., Henkin Y., et al. Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008, 359(3):229-241.
11. Mitrou P.N., Kipnis V., Thiébaut A.C., et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 2007, 167:2461-2468.
12. McManus K., Antinoro L., Sacks F. A randomized controlled trial of a moderate-fat, low-energy diet compared with a low fat, low-energy diet for weight loss in overweight adults. Int J Obes Relat Metab Disord 2001, 25(10):1503-1511.
13. Blanck H.M., Khan L.K., Serdula M.K. Use of nonprescription weight loss products. Results from a multistate survey. JAMA 2001, 286:930-935.
14. Pittler M.H., Stevinson C., Ernst E. Chromium picolonate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord 2003, 27(4):522-529.
15. Martin J., Wang Z.Q., Zhang X.H., et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006, 29(8):1826-1832.
16. Lukaski H.C., Siders W.A., Penland J.G. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. Nutrition 2007, 23(3):187-195. [Epub 2007 Feb 8].
17. Hackman R.M., Havel P.J., Schwartz H.J., et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. Int J Obes (Lond) 2006, 30(10):1545-1556.
18. Shekelle P.G., Hardy M.L., Morton S.C., et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003, 289(12):1537-1545.
19. Natural Standard, Natural Standard Database. Available at: Accessed February 5, 2010. http://www.naturalstandard.com.
20. Haaz S., Fontaine K.R., Cutter G., et al. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev 2006, 7(1):79-88.
21. West D.B., Delany J.P., Camet P.M., et al. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998, 275(3 Pt 2):R667-R672.
22. Dugan M.E.R., Aalhus A.L., Schaefer A.L., et al. The effects of conjugated linoleic acid on fat to lean repartitioning and feed conversion in pigs. Can J Anim Sci 1997, 77:723-725.
23. Blankson H., Stakkestad J.A., Fagertun H., et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr 2000, 130(12):2943-2948.
24. Gaullier J.M., Halse J., Høye K., et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr 2004, 79(6):1118-1125.
25. Kamphuis M.M., Lejeune M.P., Saris W.H., et al. The effect of conjugated linoleic acid supplementation after weight loss on body weight regain, body composition, and resting metabolic rate in overweight subjects. Int J Obes 2003, 27:840-847.
26. Syvertsen C., Halse J., Høivik H.O., et al. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese. Int J Obes 2007, 31(7):1148-1154.
27. Jull A.B., Mhurchu C.N., Bennett D.A., et al. Chitosan for overweight or obesity. Cochrane Database Syst Rev 2008, (3). CD003892.
28. Teng L., Barnes J. Chinese herbal medicines for weight loss (protocol). Cochrane Database Syst Rev 2007, (1). CD006381. DOI: 10.1002/14651858.CD006381.
29. Cabýoglu M.T., Ergene N., Tan U. The treatment of obesity by acupuncture. Int J Neurosci 2006, 116(2):165-175.
30. Lacey J.M., Tershakovec A.M., Foster G.D. Acupuncture for the treatment of obesity: a review of the evidence. Int J Obes Relat Metab Disord 2003, 27(4):419-427.
31. Ernst E. Acupuncture/acupressure for weight reduction? A systematic review. Wien Klin Wochenschr 1997, 109(2):60-62.
32. Cochrane G. Hypnosis and weight reduction: which is the cart and which is the horse?. Am J Clin Hypn 1992, 35(2):109-118.
33. Barabasz M. Efficacy of hypnotherapy in the treatment of eating disorders. Int J Clin Exp Hypn 2007, 55(3):318-335.
34. Van Dorsten B., Lindley E.M. Cognitive and behavioral approaches in the treatment of obesity. Endocrinol Metab Clin North Am 2008, 37(4):905-922.
35. Corbalán M.D., Morales E.M., Canteras M., et al. Effectiveness of cognitive-behavioral therapy based on the Mediterranean diet for the treatment of obesity. Nutrition 2009, 25(7-8):861-869.
36. 2007 National diabetes fact sheet. 2008, National Center for Chronic Disease Prevention and Health Promotion. Available at: , and Accessed February 5, 2010. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.
37. Chang H.Y., Wallis M., Tiralongo E. Use of complementary and alternative medicine among people living with diabetes: literature review. J Adv Nurs 2007, 58(4):307-319.
38. Mertz W. Interaction of chromium with insulin: a progress report. Nutr Rev 1998, 56:174-177.
39. Institute of Medicine.Food and Nutrition Board Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc 2001, N.A. Press, Washington, DC.
40. Davis C.M., Vincent J.B. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 1997, 36:4382-4385.
41. Althuis M.D., Jordan N.E., Ludington E.A., et al. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr 2002, 76:148-155.
42. Ryan G.J., Wanko N.S., Redman A.R., et al. Chromium as adjunctive treatment for type 2 diabetes. Ann Pharmacother 2003, 37:876-885.
43. Balk E.M., Tatsioni A., Lichtenstein A.H., et al. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007, 30:2154-2163.
44. Sargeant L.A., Wareham N.J., Bingham S., et al. Vitamin C and hyperglycemia in the European prospective investigation into cancer - Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care 2000, 23:726-732.
45. Harding A.H., Wareham N.J., Bingham S.A., et al. Plasma vitamin C level, fruit and vegetable consumption, and the risk of new-onset type 2 diabetes mellitus: the European prospective investigation of cancer - Norfolk prospective study. Arch Intern Med 2008, 168(14):1493-1499.
46. Gaede P., Poulsen H.E., Parving H.H., et al. Doubleblind, randomized study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 2001, 18:756-760.
47. Farvid M.S., Jalali M., Siassi F., et al. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005, 28:2458-2464.
48. Smith A.R., Shenvi S.V., Widlansky M., et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004, 11:1135-1146.
49. Ziegler D., Nowak H., Kempler P., et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004, 21:114-121.
50. Ziegler D., Ametov A., Barinov A., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006, 29(11):2365-2370.
51. Ahmed I., Chandranath I., Sharma A.K., et al. Mechanism of hypoglycemic action of Momordica charantia fruit juice in normal and diabetic rats. J Physiol 1999, 520:25.
52. Srivastava Y., Venkatakrishna-Bhatt H., Verma Y., et al. Retardation of retinopathy by Momordica charantia L. (bitter ground) fruit extract in alloxan diabetic rats. Indian J Exp Biol 1987, 25:571-572.
53. Srivastava Y., Venkatakrishna-Bhatt H., Verma Y. Effect of Momordica charantia Linn. Pomous aqueous extract on cataractogenesis in murrin alloxan diabetics. Pharmacol Res Commun 1988, 20:201-209.
54. Ahmad F., Khan M.M., Rastogi A.K., et al. Effect of (2)epicatechin on cAMP content, insulin release and conversion of proinsulin to insulin in immature and mature rat islets in vitro. Indian J Exp Biol 1991, 29:516-520.
55. Dans A.M., Villarruz M.V., Jimeno C.A., et al. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 2007, 60(6):554-559.
56. Jarvill-Taylor K.J., Anderson R.A., Graves D.J. A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. J Am Coll Nutr 2001, 20:327-336.
57. Anderson R.A., Broadhurst C.L., Polansky M.M., et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem 2004, 52:65-70.
58. Solomon T.P.J., Blannin A.K. Effects of short-term cinnamon ingestion on in vivo glucose tolerance. Diabetes Obes Metab 2007, 9:895-901.
59. Mang B., Wolters M., Schmitt B., et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest 2006, 36:340-344.
60. Vanschoonbeek K., Thomassen B.J., Senden J.M., et al. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr 2006, 136:977-980.
61. Khan A., Safdar M., Ali Khan M.M., et al. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 2003, 26(12):3215-3218.
62. Hannan J.M., Ali L., Rokeya B., et al. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br J Nutr 2007, 97(3):514-521.
63. Xue W.L., Li X.S., Zhang J., et al. Effect of Trigonella foenum-graecum (fenugreek) extract on blood glucose, blood lipid and hemorheological properties in streptozotocin-induced diabetic rats. Asia Pac J Clin Nutr 2007, 16(Suppl 1):422-426.
64. Sharma R.D., Raghuram T.C., Rao N.S. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. Eur J Clin Nutr 1990, 44(4):301-306.
65. Gupta A., Gupta R., Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India 2001, 49:1057-1061.
66. Bone K, Gymnema: a key herb in the management of diabetes, in Townsend Letter for Doctors & Patients December 1, 2002 [online].
67. Porchezhian E., Dobriyal R. An overview on the advances of Gymnema sylvestre: chemistry, pharmacology and patents. Pharmazie 2003, 58:5-12.
68. Shanmugasundaram K., Panneerselvam C., Samudram P., et al. Enzyme changes and glucose utilisation in diabetic rabbits: The effect of Gymnema sylvestre. R Br J Ethnopharmacol 1983, 7:205-234.
69. Shanmugasundaram E.R., Gopinath K.L., Radha Shanmugasundaram K., et al. Possible regeneration of the islets of Langerhans in streptozocin-diabetic rats given Gymnema sylvestre leaf extracts. J Ethnopharmacol 1990, 30(3):265-279.
70. Leach M.J. Gymnema sylvestre for diabetes mellitus: a systematic review. J Altern Complement Med 2007, 13(9):977-983.
71. Baskaran K., Kizar Ahamath B., Radha Shanmugasundaram K., et al. Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol 1990, 30:295-305.
72. Shanmugasundaram E.R., Rajeswari G., Baskaran K., et al. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol 1990, 30:281-294.
73. Ennouri M., Fetoui H., Bourret E., et al. Evaluation of some biological parameters of Opuntia ficus indica. 1. Influence of a seed oil supplemented diet on rats. Bioresour Technol 2006, 97(12):1382-1386.
74. Laurenz J., Collier C., Kuti J. Hypoglycaemic effect of Opuntia lindheimeri Englem in a diabetic pig model. Phytother Res 2003, 17(1):26-29.
75. Ennouri M., Fetoui H., Bourret E., et al. Evaluation of some biological parameters of Opuntia ficus indica. 2. Influence of seed supplemented diet on rats. Bioresour Technol 2006, 97(16):2136-2140.
76. Frati-Munari A.C., Gordillo B.E., Altamirano P., et al. Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care 1988, 11(1):63-66.
77. Frati-Munari A.C., Fernández-Harp J.A., Bañales-Ham M., et al. Decreased blood glucose and insulin by nopal (Opuntia sp.). Arch Invest Med (Mex) 1983, 14(3):269-274.
78. Wang E., Wylie-Rosett J. Review of selected Chinese herbal medicines in the treatment of type 2 diabetes. Diabetes Educ 2008, 34(4):645-654.
79. Jia W., Gao W., Tang L. Antidiabetic herbal drugs officially approved in China. Phytother Res 2003, 17:1127-1134.
80. Grabowska M.J. The effect of hypnosis and hypnotic suggestion on the blood flow in the extremities. Pol Med J 1971, 10(4):1044-1051.
81. Rosenzweig S., Reibel D.K., Greeson J.M., et al. Mindfulness-based stress reduction is associated with improved glycemic control in type 2 diabetes mellitus: a pilot study. Altern Ther Health Med 2007, 13(5):36-38.
82. Pomposelli R., Piasere V., Andreoni C., et al. Observational study of homeopathic and conventional therapies in patients with diabetic polyneuropathy. Homeopathy 2009, 98(1):17-25.
83. Higashimura Y., Shimoju R., Maruyama H., et al. Electro-acupuncture improves responsiveness to insulin via excitation of somatic afferent fibers in diabetic rats. Auton Neurosci 2009, 150(1):100-103.
84. Ishizaki N., Okushi N., Yano T., et al. Improvement in glucose tolerance as a result of enhanced insulin sensitivity during electroacupuncture in spontaneously diabetic Goto-Kakizaki rats. Metabolism 2009, 58(10):1372-1378.
85. Feng M., Li Y., Pang B., et al. Acupuncture combined with application of xiaoke plaster for treatment of 309 cases of diabetes mellitus. J Tradit Chin Med 1997, 17(4):247-249.
86. Chang C.S., Ko C.W., Wu C.Y., et al. Effect of electrical stimulation on acupuncture points in diabetic patients with gastric dysrhythmia: a pilot study. Digestion 2001, 64(3):184-190.
87. Ahn A.C., Bennani T., Freeman R., et al. Two styles of acupuncture for treating painful diabetic neuropathy-a pilot randomised control trial. Acupunct Med 2007, 25(1-2):11-17.
88. Abuaisha B.B., Costanzi J.B., Boulton A.J. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998, 39(2):115-121.
89. Grundy S.M., Brewer H.B., Cleeman J.L., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433.
90. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745.
91. Adams R.J., Appleton S., Wilson D.H., et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care 2005, 28:2777.
92. Kraja A.T., Rao D.C., Weder A.B., et al. An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab (Lond) 2005, 2:17.
93. Sone H., Mizuno S., Fujii H., et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients?. Diabetes Care 2005, 28(6):1463-1471.
94. Dubowitz T., Heron M., Bird C.E., et al. Neighborhood socioeconomic status and fruit and vegetable intake among whites, blacks, and Mexican Americans in the United States. Am J Clin Nutr 2008, 87:1883-1891.
95. Regitz-Zagrosek V., Lehmkuhl E., Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007, 4(Suppl B):S162-S177.
96. Qiao Q., DECODE Study Group Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006, 49(12):2837-2846.
97. Laaksonen D.E., Toppinen L.K., Juntunen K.S., et al. Dietary carbohydrate modification enhances insulin secretion in persons with the metabolic syndrome. Am J Clin Nutr 2005, 82(6):1218-1227.
98. Lerman R.H., Toppinen L.K., Juntunen K.S., et al. Dietary soya intake alters plasma antioxidant status and lipid peroxidation in postmenopausal women with the metabolic syndrome. Br J Nutr 2007, 98(4):807-813.
99. Orchard T.J., Temprosa M., Goldberg R., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142(8):611-619.
100. Minich D.M., Bland J.S. Dietary management of the metabolic syndrome beyond macronutrients. Nutr Rev 2008, 66(8):429-444.
101. Feldeisen S.E., Tucker K.L. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 2007, 32(1):46-60.
102. Lerman R.H., Minich D.M., Darland G., et al. Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial. Nutr Metab (Lond) 2008, 5:29.
103. Rimbach G., Boesch-Saadatmandi C., Frank J., et al. Dietary isoflavones in the prevention of cardiovascular disease - a molecular perspective. Food Chem Toxicol 2008, 46:1308-1319.
104. Noriega-Lopez L., Tovar A.R., Gonzalez-Granillo M., et al. Pancreatic insulin secretion in rats fed a soy protein high fat diet depends on the interaction between the amino acid pattern and isoflavones. J Biol Chem 2007, 282:20657-20666.
105. Taku K., Umegaki K., Sato Y., et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2007, 85(4):1148-1156.
106. Azadbakht L., Kimiagar M., Mehrabi Y., et al. Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. Am J Clin Nutr 2007, 85:735-741.
107. Azadbakht L., Kimiagar M., Mehrabi Y., et al. Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. Diabetes Care 2007, 30:967-973.
108. Mukuddem-Petersen J., Oosthuizen W., Jerling J.C. A systematic review of the effects of nuts on blood lipid profiles in humans. J Nutr 2005, 135(9):2082-2089.
109. Griel A.E., Kris-Etherton P.M. Tree nuts and the lipid profile: a review of clinical studies. Br J Nutr 2006, 96(Suppl 2):S68-S78.
110. Qualified health claims: letter of enforcement discretion - nuts and coronary heart disease [Docket No 02P-0505] 2007, Office of Nutritional Products, Labeling and Dietary Supplements, Food and Drug Administration.
111. Qualified health claims: letter of enforcement discretion - walnuts and coronary heart disease [Docket No. 02P-0292] 2004, Office of Nutritional products, Labeling and Dietary Supplements, Food and Drug Administration.
112. Kris-Etherton P.M., Hu F.B., Ros E., et al. The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. J Nutr 2008, 138:1746S-1751S.
113. Gebauer S.K., West S.G., Kay C.D., et al. Effects of pistachios on cardiovascular disease risk factors and potential mechanisms of action: a dose-response study. Am J Clin Nutr 2008, 88(3):651-659.
114. Jenkins D.J., Kendall C.W., Josse A.R., et al. Almonds decrease postprandial glycemia, insulinemia, and oxidative damage in healthy individuals. J Nutr 2006, 136(12):2987-2992.
115. Zibaeenezhad M.J., Shamsnia S.J., Khorasani M. Walnut consumption in hyperlipidemic patients. Angiology 2005, 56(5):581-583.
116. Meletis C.D., Barker J. Natural treatments for metabolic syndrome. Alternative and Complementary Therapies 2003, 9(6):289-293.